EUCTR2009-011589-27-PL进行中（未招募）不适用
A Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV337 in Patients with Type 2 Diabetes on Metformin Monotherapy
aboratoires Fournier S.A. A Solvay Pharmaceuticals company0 个研究点目标入组 56 人开始时间: 2009年7月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female of non-childbearing potential, aged 18 to 75 years inclusive.
- •2. Diagnosed with T2DM defined by the American Diabetes Association criteria: FPG
- •=7.0 mmol/L (126 mg/dL), or two hours postprandial glucose =11.1 mmol/L
- •(200 mg/dL).
- •3. Treated with life style modification and stable dose of metformin monotherapy, =850 mg daily dose, for at least three months; the dose of metformin, physical exercise and dietary recommendations will stay unchanged during the whole duration of the study.
- •4. With inadequate glycemic control, defined by hemoglobin A1c (HbA1c) =7%, but <10%.
- •5. With FPG <15 mmol/L (270 mg/dl).
- •6. If female, the subject should be of non-childbearing potential, defined as being
- •post-menopausal for at least 24 months prior to dosing (with confirmed estradiol
- •=20 pg/mL [73 pmol/L] and follicle-stimulating hormone =40 mIU/mL) at Screening if
- •less than 60 years old, or surgically sterilized (with negative pregnancy test at Screening in the absence of hysterectomy). If male, unless the subject has undergone a vasectomy, he must abstain from sexual contact with women who may become pregnant, or use a combination of a condom and spermicide as a contraception measure from the first dosing up to three months after the last intake of study drug.
- •7. Subjects will have given their voluntary written informed consent to participate in the study in their own language and be willing to comply with the protocol. Consent will be documented by the subject’s name and dated signature prior to screening procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Type 1 diabetes mellitus, maturity onset diabetes of the young.
- •2. C-peptide <0.27 nmol/L (0.8 ng/mL).
- •3. Currently treated or treated during the last three months with insulin therapy.
- •4. Ongoing oral dual anti-diabetic therapy or treated during the last three months by oral anti-diabetic therapy other than metformin.
- •5. Treatment with a fibrate, ezetimibe or with any lipid lowering agents other than statins.
- •6. Treatment with warfarin and other coumarinic derivatives (i.e. acenocoumarol).
- •7. Body mass index >40.0 kg/m2.
- •8. Uncontrolled arterial hypertension defined by systolic blood pressure (SBP) =160 and/or diastolic blood pressure (DBP) =95 mmHg taken in a semi-recumbent position, after 5 minutes rest.
- •9. Renal failure or renal dysfunction defined by creatinine clearance <60 mL/min as
- •calculated with the Modification of Diet in Renal Disease formula as follows:eGFR (mL/min/1.73m2)= 175 x [SerumCreatinine(µmol/L) x 0.0113]-1.154
- •x Age(years)-0.203 (x 0.742 if female). For African-Americans the value should be
- •multiplied by 1.21.
- •Note: values <60 mL/min are likely to deviate from the true value.
- •10. History of proliferative retinopathy or maculopathy requiring, or previously treated with, laser therapy.
- •11. Evidence of unstable cardiovascular diseases: 1) coronary bypass surgery, or angioplasty within three months of the screening visit; 2) myocardial infarction, unstable angina pectoris or other significant cardiac event (including history of cardiac arrhythmias or conduction delays on electrocardiogram [ECG]) or cerebral stroke within three months of the screening visit; 3) severe peripheral artery disease as evidenced by intermittent claudication within three months of the screening visit; 4) peripheral artery surgery within three months of the screening visit.
- •12. Heart failure New York Heart Association class I to IV.
- •13. History of pancreatitis or gall bladder disease, with the exception of subjects with gall bladder disease who have previously undergone a cholecystectomy.
- •14. History of gastric surgery, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.
- •15. History of gastric or duodenal ulcer within three months of the screening visit.
- •16. History of diagnosis of hepatitis B or hepatitis C.
- •17. History of solid organ transplant.
- •18. History of diagnosed hereditary or acquired myopathy.
- •19. History of mental instability, drug or alcohol abuse or subject who was treated for severe psychiatric illness, which, in the opinion of the Investigator, may interfere with optimal participation in the study.
- •20. History of cancer (except basal cell carcinoma or squamous cell skin cancer).
- •21. Evidence of other relevant diseases not related to T2DM as revealed by history, physical examination and laboratory assessments which are deemed to limit study evaluation or participation in the judgment of the Investigator.
- •22. Alanine aminotransferase (ALT) = two times upper limit of normal.
- •23. Known to be positive to the human immunodeficiency virus (HIV)1 or HIV2 virus.
- •24. Known hypersensitivity to the excipients of SLV337 capsules (lactose monohydrate, sucrose, hydroxypropyl methylcellulose, sodium lauryl sulfate, sodium docusate, purified water, sodium starch glycolate and magnesium stearate).
- •25. Has taken one single dose of an investigational drug within 30 days or multiple doses of an investigational drug within 60 days prior to dosing.
- •26. Has an acute infection a
研究者
相似试验
进行中（未招募）
1 期
Evaluation of Dupilumab in Children with Uncontrolled Asthma (Liberty Asthma Voyage)MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-001607-23-HUSanofi-Aventis Recherche & Développement785
进行中（未招募）
1 期
Effect of Efpeglenatide on Cardiovascular OutcomesType 2 diabetes mellitusMedDRA version: 21.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-002954-35-FIsanofi-aventis recherche & développement5,000
进行中（未招募）
1 期
A Clinical Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s DiseaseEarly Alzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2020-000116-30-SEJanssen-Cilag International NV420
进行中（未招募）
1 期
Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskType 2 diabetes mellitusChronic kidney diseaseMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2017-002644-32-NOSANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT16,154
进行中（未招募）
1 期
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn’s DiseaseModerately to Severely Active Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-006165-11-PLJanssen-Cilag International NV350